Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee Vacancies Remain High As FDA Revs Up Search Efforts

Executive Summary

With its recent hiring push drawing attention, FDA is quietly undertaking another recruitment effort - filling advisory committee roster vacancies

You may also be interested in...



PDUFA Talks: Four-Phase Review Flops; Automatic Extensions Back On Table

FDA and industry have moved to a more pointed debate of automatic review deadline extensions after the agency decided to drop its four-phase review process proposal.

PDUFA Talks: Four-Phase Review Flops; Automatic Extensions Back On Table

FDA and industry have moved to a more pointed debate of automatic review deadline extensions after the agency decided to drop its four-phase review process proposal.

FDA Using More Temporary Advisory Committee Members To Fill Vacancies

FDA advisory committees are increasingly relying on temporary members to fill their ranks - a trend that could result in less predictability for drug sponsors at a make-or-break review meeting

Related Content

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel